登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《Nature，12月4日，Correlates of protection against SARS-CoV-2 in rhesus macaques》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-12-23

  • Correlates of protection against SARS-CoV-2 in rhesus macaques
    Katherine McMahan, Jingyou Yu, […]Dan H. Barouch
    Nature (2020)

    Abstract
    Recent studies have reported protective efficacy of both natural immunity1 and vaccine-induced immunity2–7 against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) challenge in rhesus macaques. However, the importance of humoral and cellular immunity for protection against SARS-CoV-2 infection remains to be determined. Here we show that adoptive transfer of purified IgG from convalescent macaques protects naïve recipient rhesus macaques against SARS-CoV-2 challenge in a dose dependent fashion. Depletion of CD8+ T cells in convalescent animals partially abrogated the protective efficacy of natural immunity against SARS-CoV-2 re-challenge, suggesting the importance of cellular immunity in the context of waning or subprotective antibody titers. These data demonstrate that relatively low antibody titers are sufficient for protection against SARS-CoV-2 in rhesus macaques, and that cellular immune responses may also contribute to protection if antibody responses are suboptimal. We also show that higher antibody titers are required for therapy of SARS-CoV-2 infection in macaques. These findings have important implications for the development of SARS-CoV-2 vaccines and immune-based therapeutics.

  • 原文来源：https://www.nature.com/articles/s41586-020-03041-6
181浏览量
原文链接
相关报告

  • 《Science，5月20日，DNA vaccine protection against SARS-CoV-2 in rhesus macaques》
    • 来源专题：COVID-19科研动态监测
    • 编译者：xuwenwhlib
    • 发布时间：2020-05-21
    • DNA vaccine protection against SARS-CoV-2 in rhesus macaques View ORCID ProfileJingyou Yu1,*, View ORCID ProfileLisa H. Tostanoski1,*, View ORCID ProfileLauren Peter1,*, View ORCID ProfileNoe B. Mercado1,*, View ORCID ProfileKatherine McMahan1,*, View ORCID ProfileShant H. Mahrokhian1,*, View ORCID ProfileJoseph P. Nkolola1,*, View ORCID ProfileJinyan Liu1,*, Zhenfeng Li1,*, View ORCID ProfileAbishek Chandrashekar1,*, David R. Martinez2, View ORCID ProfileCarolin Loos3, View ORCID ProfileCaroline Atyeo3, View ORCID ProfileStephanie Fischinger3, View ORCID ProfileJohn S. Burke3, View ORCID ProfileMatthew D. Slein3, Yuezhou Chen4, View ORCID ProfileAdam Zuiani4, View ORCID ProfileFelipe J. N. Lelis4, Meghan Travers4, View ORCID ProfileShaghayegh Habibi4, View ORCID ProfileLaurent Pessaint5, View ORCID ProfileAlex Van Ry5, View ORCID ProfileKelvin Blade5, Renita Brown5, Anthony Cook5, View ORCID ProfileBrad Finneyfrock5, View ORCID ProfileAlan Dodson5, Elyse Teow5, Jason Velasco5, View ORCID ProfileRoland Zahn6, View ORCID ProfileFrank Wegmann6, View ORCID ProfileEsther A. Bondzie1, View ORCID ProfileGabriel Dagotto1, View ORCID ProfileMakda S. Gebre1, Xuan He1, View ORCID ProfileCatherine Jacob-Dolan1, Marinela Kirilova1, View ORCID ProfileNicole Kordana1, Zijin Lin1, View ORCID ProfileLori F. Maxfield1, Felix Nampanya1, View ORCID ProfileRamya Nityanandam1, View ORCID ProfileJohn D. Ventura1, View ORCID ProfileHuahua Wan1, View ORCID ProfileYongfei Cai7, View ORCID ProfileBing Chen7,8, View ORCID ProfileAaron G. Schmidt3,8, View ORCID ProfileDuane R. Wesemann4,8, View ORCID ProfileRalph S. Baric2, View ORCID ProfileGalit Alter3,8, View ORCID ProfileHanne Andersen5, View ORCID ProfileMark G. Lewis5, View ORCID ProfileDan H. Barouch1,3,8,† See all authors and affiliations Science 20 May 2020: eabc6284 DOI: 10.1126/science.abc6284 Abstract The global COVID-19 pandemic caused by the SARS-CoV-2 virus has made the development of a vaccine a top biomedical priority. In this study, we developed a series of DNA vaccine candidates expressing different forms of the SARS-CoV-2 Spike (S) protein and evaluated them in 35 rhesus macaques. Vaccinated animals developed humoral and cellular immune responses, including neutralizing antibody titers comparable to those found in convalescent humans and macaques infected with SARS-CoV-2. Following vaccination, all animals were challenged with SARS-CoV-2, and the vaccine encoding the full-length S protein resulted in >3.1 and >3.7 log10 reductions in median viral loads in bronchoalveolar lavage and nasal mucosa, respectively, as compared with sham controls. Vaccine-elicited neutralizing antibody titers correlated with protective efficacy, suggesting an immune correlate of protection. These data demonstrate vaccine protection against SARS-CoV-2 in nonhuman primates.
    161浏览量
    原文链接

  • 《Nature，5月12日，Respiratory disease in rhesus macaques inoculated with SARS-CoV-2》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-05-13
    • Respiratory disease in rhesus macaques inoculated with SARS-CoV-2 Vincent J. Munster, Friederike Feldmann, Brandi N. Williamson, Neeltje van Doremalen, Lizzette Pérez-Pérez, Jonathan Schulz, Kimberly Meade-White, Atsushi Okumura, Julie Callison, Beniah Brumbaugh, Victoria A. Avanzato, Rebecca Rosenke, Patrick W. Hanley, Greg Saturday, Dana Scott, Elizabeth R. Fischer & Emmie de Wit Nature (2020) Abstract An outbreak of a novel coronavirus, named SARS-CoV-2, causing respiratory disease and a ~2% case fatality rate started in Wuhan, China in December 20191,2. Following unprecedented global spread3, the World Health Organization declared COVID-19 a pandemic on March 11, 2020. Although data on disease in humans are emerging at a steady pace, certain aspects of the pathogenesis of SARS-CoV-2 can only be studied in detail in animal models, where repeated sampling and tissue collection is possible. Here, we show that SARS-CoV-2 causes respiratory disease in infected rhesus macaques, with disease lasting 8-16 days. Pulmonary infiltrates, a hallmark of human disease, were visible in lung radiographs. High viral loads were detected in swabs from the nose and throat of all animals as well as in bronchoalveolar lavages; in one animal we observed prolonged rectal shedding.
    228浏览量
    原文链接